New drugs that might fly in 2022

Posted 21 December 2021 AM

Nearly half of the new medicines recommended for approval by the CHMP this month, have either already been green-lighted by the TGA or are currently under review, signalling Australia is catching up to its European counterpart and hinting at what is likely to come early 2022.

In its last meeting for the year, the EMA's advisory committee gave the nod to nine new medicines, three of which have been TGA approved, including Pfizer's once-weekly, long-acting, recombinant growth hormone Ngenla, and Bayer's treatment for chronic kidney disease associated with type 2 diabetes in adults, Kerendia. Both medicines were TGA approved in November.

To see the whole article, please login